UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

Annals of oncology, 2018-04, Vol.29 (4), p.888-894

2018

Volltextzugriff (PDF)

PG 5.01 Targeting CDK 4–6 pathway

Breast (Edinburgh), 2015-03, Vol.24, p.S9-S9

2015

Volltextzugriff (PDF)

317 Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies

European journal of cancer (1990), 2015-09, Vol.51, p.S60-S60

2015

Volltextzugriff (PDF)

498 CDK4/6 inhibitor (LY2835219) exhibits potent anti-tumor activity in human lung cancer cell lines with intact retinoblastoma

European journal of cancer (1990), 2014-11, Vol.50, p.162-162

2014

Volltextzugriff (PDF)

558 Dual Targeting of ADAM10 and ADAM17 as a Novel Therapy for Breast Cancer

European journal of cancer (1990), 2012-11, Vol.48, p.171-171

2012

Volltextzugriff (PDF)

Prognostic classification of breast ductal carcinoma-in-situ

The Lancet (British edition), 1995-05, Vol.345 (8958), p.1154-1157

1995

Volltextzugriff (PDF)

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

Annals of oncology, 2021-08, Vol.32 (8), p.1015-1024

2021

Volltextzugriff (PDF)

145 PP2A – a Novel Target for the Treatment of Lapatinib-resistant Breast Cancer

European journal of cancer (1990), 2012-11, Vol.48, p.45-45

2012

Volltextzugriff (PDF)

1049 POSTER Increased Amplification of HER2 in a Cell Line Model of Acquired Lapatinib Resistance

European journal of cancer (1990), 2011, Vol.47, p.S110-S110

2011

Volltextzugriff (PDF)

FOXA1 represses the molecular phenotype of basal breast cancer cells

Oncogene, 2013-01, Vol.32 (5), p.554-563

2013

Volltextzugriff (PDF)

Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer

Gynecologic oncology, 2023-03, Vol.170, p.221-228

2023

Volltextzugriff (PDF)

Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer

Gynecologic oncology, 2021-12, Vol.163 (3), p.465-472

2021

Volltextzugriff (PDF)

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy

Annals of oncology, 2005-11, Vol.16 (11), p.1772-1777

2005

Volltextzugriff (PDF)

Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3

Annals of oncology, 2018-10, Vol.29, p.viii708-viii708

2018

Volltextzugriff (PDF)

Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1

Annals of oncology, 2006-04, Vol.17 (4), p.597-604

2006

Volltextzugriff (PDF)

Phase II Study of Palbociclib (PD-0332991) + Letrozole vs Letrozole Alone in First-Line ER + /HER2- Advanced Breast Cancer

Annals of oncology, 2013-11, Vol.24, p.ix32-ix32

2013

Volltextzugriff (PDF)

Final results of a phase II study of bevacizumab plus docetaxel for the first-line treatment of metastatic breast cancer (TORI-B01)

European journal of cancer supplements, 2008, Vol.6 (7), p.217-217

2008

Volltextzugriff (PDF)

557 POSTER Pre-clinical activity of the PARP inhibitor AZD2281 in homologous recombination repair deficient triple negative breast cancer

European journal of cancer supplements, 2008, Vol.6 (12), p.175-176

2008

Volltextzugriff (PDF)

Clinical Patterns of Palbociclib Associated Neutropenia in the Paloma-1/Trio-18 Trial

Annals of oncology, 2014-09, Vol.25, p.iv122

2014

Volltextzugriff (PDF)

100O Results of A Randomized Phase 2 Study of Pd 0332991, A Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, In Combination with Letrozole vs Letrozole Alone For First-Line Treatment of ER + /Her2- Advanced Breast Cancer (Bc)

Annals of oncology, 2012-05, Vol.23, p.ii43

2012

Volltextzugriff (PDF)

Expression of a Multidrug-Resistance Gene in Human Tumors and Tissues

Proceedings of the National Academy of Sciences - PNAS, 1987-01, Vol.84 (1), p.265-269

1987

Volltextzugriff (PDF)

368PCLINICAL PATTERNS OF PALBOCICLIB ASSOCIATED NEUTROPENIA IN THE PALOMA-1/TRIO-18 TRIAL

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv122-iv122

2014

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(33)
Webseiten
(2)

Sprache

Englisch
(35)
Japanisch
(3)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

PG 5.01 Targeting CDK 4–6 pathway

317 Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies

498 CDK4/6 inhibitor (LY2835219) exhibits potent anti-tumor activity in human lung cancer cell lines with intact retinoblastoma

558 Dual Targeting of ADAM10 and ADAM17 as a Novel Therapy for Breast Cancer

Prognostic classification of breast ductal carcinoma-in-situ

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

145 PP2A – a Novel Target for the Treatment of Lapatinib-resistant Breast Cancer

1049 POSTER Increased Amplification of HER2 in a Cell Line Model of Acquired Lapatinib Resistance

FOXA1 represses the molecular phenotype of basal breast cancer cells

Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer

Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy

Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3

Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1

Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

LBA7_PR - Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

Phase II Study of Palbociclib (PD-0332991) + Letrozole vs Letrozole Alone in First-Line ER + /HER2- Advanced Breast Cancer

Final results of a phase II study of bevacizumab plus docetaxel for the first-line treatment of metastatic breast cancer (TORI-B01)

557 POSTER Pre-clinical activity of the PARP inhibitor AZD2281 in homologous recombination repair deficient triple negative breast cancer

Clinical Patterns of Palbociclib Associated Neutropenia in the Paloma-1/Trio-18 Trial

100O Results of A Randomized Phase 2 Study of Pd 0332991, A Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, In Combination with Letrozole vs Letrozole Alone For First-Line Treatment of ER + /Her2- Advanced Breast Cancer (Bc)

Expression of a Multidrug-Resistance Gene in Human Tumors and Tissues

368PCLINICAL PATTERNS OF PALBOCICLIB ASSOCIATED NEUTROPENIA IN THE PALOMA-1/TRIO-18 TRIAL

Suchergebnisse filtern